Investors NewsSearch: Nov 22, 2021Rafael Holdings Realigns Leadership Team to Support Earlier Stage Pipeline Focus Oct 28, 2021Rafael Holdings Provides Update on Rafael Pharmaceuticals' Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia Oct 18, 2021Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08 Oct 18, 2021Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2021 Financial and Operating Results and Provides Business Update Oct 06, 2021Rafael Holdings Appoints Mimi Huizinga, MD, MPH as Chief Development and Medical Officer Sep 24, 2021Rafael Holdings Continues to Expand its Management Team with a Highly Experienced Global Biopharmaceutical Executive to Build a Fully Integrated Cancer Metabolism Therapeutics Company and Announces Inducement Grant Under NYSE Rule 303A.08 Sep 17, 2021Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08 Sep 14, 2021Rafael Holdings Appoints Patrick Fabbio as Chief Financial Officer Aug 24, 2021Rafael Holdings Announces Closing of $104.2 Million Private Placement Aug 20, 2021Rafael Holdings Announces $104.2 Million Private Placement 1 2 3 4 5 6 7 << < > >>
